Author: David Fisher

LogicBio Therapeutics Granted FDA Orphan Drug Designation for LB-001 to Treat Methylmalonic Acidemia

LogicBio Therapeutics Granted FDA Orphan Drug Designation for LB-001 to Treat Methylmalonic Acidemia

LogicBio Therapeutics, Inc. (LOGC), a genome editing company, reported that the US Food and Drug Administration (FDA) has granted orphan drug designation to LB-001, a recombinant adeno-associated viral vector with human methylmalonyl-COA mutase (MUT) gene for the treatment of methylmalonic acidemia (MMA). “We believe that LB-001 has potential to transform the treatment of this devastating disease,” said Chief Executive Fred […]

Durable-Goods Orders Rise 2.7% in March, Led Higher by Transportation Equipment

Durable-Goods Orders Rise 2.7% in March, Led Higher by Transportation Equipment

Orders for durable goods rose 2.7% in March, sailing past expectations and the previous month’s revised decline of 1.1%, the Commerce Department said Thursday. March’s orders were bolstered by a 7% jump in transportation equipment. Excluding transportation, new orders rose 0.4% last month. Econoday had predicted a 0.7% advance for new orders and a 0.2% gain excluding transportation. “The guts […]